- Home
- IVVD vs SSSS Comparison
IVVD vs SSSS Comparison
Compare IVVD & SSSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVVD
- SSSS
- Stock Information
- Founded
- IVVD 2020
- SSSS 2010
- Country
- IVVD United States
- SSSS United States
- Employees
- IVVD N/A
- SSSS N/A
- Industry
- IVVD Biotechnology: Pharmaceutical Preparations
- SSSS Finance: Consumer Services
- Sector
- IVVD Health Care
- SSSS Finance
- Exchange
- IVVD Nasdaq
- SSSS Nasdaq
- Market Cap
- IVVD 116.8M
- SSSS 118.1M
- IPO Year
- IVVD 2021
- SSSS N/A
- Fundamental
- Price
- IVVD $0.70
- SSSS $4.91
- Analyst Decision
- IVVD Strong Buy
- SSSS Buy
- Analyst Count
- IVVD 5
- SSSS 2
- Target Price
- IVVD $7.11
- SSSS $6.00
- AVG Volume (30 Days)
- IVVD 581.2K
- SSSS 177.4K
- Earning Date
- IVVD 11-14-2024
- SSSS 11-07-2024
- Dividend Yield
- IVVD N/A
- SSSS N/A
- EPS Growth
- IVVD N/A
- SSSS N/A
- EPS
- IVVD N/A
- SSSS N/A
- Revenue
- IVVD $11,564,000.00
- SSSS $5,903,895.00
- Revenue This Year
- IVVD N/A
- SSSS N/A
- Revenue Next Year
- IVVD $72.22
- SSSS $6.05
- P/E Ratio
- IVVD N/A
- SSSS N/A
- Revenue Growth
- IVVD N/A
- SSSS 5.43
- 52 Week Low
- IVVD $0.71
- SSSS $3.32
- 52 Week High
- IVVD $5.20
- SSSS $5.44
- Technical
- Relative Strength Index (RSI)
- IVVD 33.40
- SSSS 53.68
- Support Level
- IVVD $0.72
- SSSS $4.81
- Resistance Level
- IVVD $0.81
- SSSS $5.44
- Average True Range (ATR)
- IVVD 0.07
- SSSS 0.27
- MACD
- IVVD -0.02
- SSSS -0.03
- Stochastic Oscillator
- IVVD 1.12
- SSSS 41.11
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.